drugset / Trial / NCT06311786

A Study to Look at How a Single Oral Dose of Carbon-14-Labelled [14C] BIIB091 Moves Through and is Processed by the Body in Healthy Male Participants

NCT06311786

Phase 1 Completed 8 enrolled Biogen
NaSingle-groupOpen-labelTreatment

Summary

The main goal of this study is to learn how \[14C\]-BIIB091 moves through and is processed by the body and to look at how much of BIIB091's metabolites (what is produced when BIIB091 is broken down by the body) appears in the blood, urine, and stool in healthy male participants. The study will also help researchers learn more about the safety of BIIB091 in healthy male participants.

Timeline

Start
2024-04-08
Primary completion
2024-05-11
Completion
2024-05-11

Drugs

EvaluationDrugModalityDoseRoute
Subject BIIB091 Small molecule Oral

Indications

No indication recorded.